Clinical trial · Observational
A Cohort Study in Newly Diagnosed MZL
A Prospective, Multi-center, Cohort Study in Newly Diagnosed Marginal Zone B-cell Lymphoma
NCT06449885CI-TRIAL-00097475recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Describe the clinical features, diagnosis and treatment status, disease course and primary outcomes of different subtypes of marginal zone B-cell lymphoma (MZL), observe the therapeutic efficacy and safety of different treatment modalities.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Marginal Zone Lymphoma | Marginal Zone Lymphoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| patients receive optimal treatment or follow-up according to the characteristics of the disease | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Newly diagnosed marginal zone lymphoma
- description
- Newly diagnosed marginal zone lymphoma，including Mucosa-associated lymphoid tissue (MALT) lymphoma, spleen MZL, and lymph node MZL, as well as primary cutaneous MZL, and pediatric NMZL.
- interventionNames
- Other: patients receive optimal treatment or follow-up according to the characteristics of the disease
Primary outcomes (1)
- measure
- Progression-free survival
- timeFrame
- assessed up to 10 years
- description
- record the period from date of patients sign informed consent until the date of documented progression or date of death from any cause, whichever came first
Secondary outcomes (7)
- measure
- Time to treatment
- timeFrame
- assessed up to 10 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age≥ 18 years old; Male or female. * Newly diagnosed marginal zone lymphoma by histopathology within the past 6 months (180 days) and no anti-tumor therapy (including chemotherapy, radiotherapy, and biological therapy or immunotherapy for the treatment of tumors). * Willing to provide biological samples required for the study, including blood samples and tumor tissue. * Voluntarily join this study and sign the informed consent form. * Willing to accept long-term follow-up. Exclusion Criteria: * Patients with HIV infection. * Those who cannot come to the hospital regularly for follow-up. * Those with comorbidities and speech impairment.
References
Publications (0)
Data not yet available
No reference posted for this study.